“Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide“

• This study from July, 2024, is the first to find that patients who were prescribed semaglutide were more likely to develop an irreversible blindness secondary to nonarteritic anterior ischemic optic neuropathy (NAION).
• Patients with diabetes who were prescribed semaglutide were more than four times more likely to be diagnosed with NAION. 
• Patients who were overweight or obese and prescribed semaglutide were more than seven times more likely to be diagnosed with NAION. 
• The study was observational, and more research is needed to confirm a direct causal link between semaglutide and NAION.